[Federal Register Volume 67, Number 49 (Wednesday, March 13, 2002)]
[Rules and Regulations]
[Pages 11229-11230]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-5060]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Ivermectin Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by Blue Ridge Pharmaceuticals, Inc. The ANADA 
provides for oral use of ivermectin tablets for prevention of heartworm 
disease in dogs.

DATES: This rule is effective March 13, 2002.

FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for 
Veterinary Medicine (HFV-102), Food and Drug

[[Page 11230]]

Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

SUPPLEMENTARY INFORMATION: Blue Ridge Pharmaceuticals, Inc., 4249-105 
Piedmont Pkwy., Greensboro, NC 27410, filed ANADA 200-270 that provides 
for veterinary prescription use of IVERHART (ivermectin) Tablets for 
prevention of canine heartworm disease by elimination of the tissue 
stage of heartworm (Dirofilaria immitis) larvae for a month after 
infection. Blue Ridge's IVERHART Tablets is approved as a generic copy 
of Merial Ltd.'s HEARTGARD Tablets, approved under NADA 138-412. ANADA 
200-270 is approved as of November 30, 2001, and 21 CFR 520.1193 is 
amended to reflect the approval. The basis of approval is discussed in 
the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
data and information submitted to support approval of this application 
may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 
between 9 a.m. and 4 p.m., Monday through Friday.
    FDA has determined under 21 CFR 25.33(d)(1) that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.
    2. Section 520.1193 is revised to read as follows:


Sec. 520.1193  Ivermectin tablets and chewables.

    (a) Specifications. (1) Each tablet or chewable contains 68, 136, 
or 272 micrograms (mcg) ivermectin.
    (2) Each chewable contains 55 or 165 mcg ivermectin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 050604 for use of tablets or chewables described in 
paragraph (a)(1) as in paragraph (d)(1) and chewables described in 
paragraph (a)(2) as in paragraph (d)(2) of this section.
    (2) No. 065274 for use of tablets described in paragraph (a)(1) as 
in paragraph (d)(1) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs. For use in dogs 6 weeks of age and 
older as follows:
    (i) Amount. 6.0 mcg per kilogram (kg) of body weight (2.72 mcg per 
pound (lb)), minimum. Up to 25 lb, 68 mcg; 26 to 50 lb, 136 mcg; 51 to 
100 lb, 272 mcg; over 100 lb, a combination of the appropriate tablets. 
Administer at monthly dosing intervals.
    (ii) Indications for use. To prevent canine heartworm disease by 
eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) 
for 1 month (30 days) after infection.
    (2) Cats. For use in cats 6 weeks of age and older as follows:
    (i) Amount. Up to 2.3 kilograms (up to 5 lb), 55 mcg; 2.3 to 6.8 
kilograms (5 to 15 lb), 165 mcg; over 6.8 kilograms (15 lb), a 
combination of the appropriate chewables (recommended minimum dose of 
24 mcg/kg of body weight (10.9 mcg/lb)). Administer once a month.
    (ii) Indications for use. To prevent feline heartworm disease by 
eliminating the tissue stage of heartworm larvae Dirofilaria immitis 
for a month (30 days) after infection, and for removal and control of 
adult and immature (L4) hookworms Ancylostoma tubaeforme and A. 
braziliense.

    Dated: January 31, 2002.
Stephen F. Sundlof,
Center for Veterinary Medicine.
[FR Doc. 02-5060 Filed 3-12-02; 8:45 am]
BILLING CODE 4160-01-S